Navigation Links
Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
Date:5/26/2010

MOUNTAIN VIEW, Calif. May 26, 2010 Complete Genomics Inc., a third-generation human genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), used the company's sequencing, bioinformatics and analytics services to sequence and compare a patient's primary lung tumor and adjacent normal tissue. Tumor-normal pairs like this allow researchers to compare the patient's genome before and after it was altered by the cancer; the patient's normal genome serves as the ideal control. This is the first time that such a comparison has been made across the whole genome for a lung cancer patient. Genentech's findings will be published online in Nature later today in a paper titled "The mutation spectrum revealed by paired genome sequences from a lung cancer patient."

Complete Genomics sequenced the patient's cancer and normal genome to a depth of 60x and 46x, respectively, providing high-resolution results and allowing somatic variations to be called with high confidence. This depth of sequencing enabled the Genentech researchers to identify a large number of somatic mutations and structural variations in the non-small cell lung cancer genome.

Using Complete Genomics' sequencing service, the Genentech team, led by Dr. Zemin Zhang, senior scientist, was able to detect significantly more somatic variations than have been discovered in other cancer studies (leukemia and breast cancer) conducted on a genome-wide basis. Genentech identified more than 50,000 high-confidence somatic single nucleotide variations (SNVs), which yielded an estimated genome-wide somatic mutation rate of 17.7 per Mb.

The Genentech researchers validated 392 somatic SNVs in coding regions, including one in the KRAS proto-oncogene. They also validated 43 large-scale structural variations in the tumor.

In addition, the researchers observed a distinct pattern of selection against mutations w
'/>"/>

Contact: Lisa Osborne
lisao@waggeneredstrom.com
206-992-5245
Complete Genomics
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
2. UCSF enters drug discovery agreement with Genentech
3. UCSF Enters Drug Discovery Agreement with Genentech
4. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
5. Now with Augmented Reality, Life Compass, by Fortune Compass, is the most complete Feng Shui App in Apple's iTunes store!
6. Impact Systems Successfully Completes EMC Documentum Migration for Global Pharmaceutical Client
7. LeveragePoint Releases Complete Online Value Management Solution
8. Vinomis Laboratories Completes Additional Funding Round
9. The Kramer Group Completes Strategic Name Change to Kramer Healthcare Technologies
10. CyberlinkASP Completes SAS 70 Type II Audit at Dallas Datacenter
11. Complete revascularization improves outcomes for CAD patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... ... An online provider of CPAP machines, masks, supplies, and accessories, My Cpap ... by offering shipping at no cost to you, directly to your door on all ... My Cpap Store is located in Las Vegas, Nevada. , Sleep apnea is a ...
(Date:8/28/2015)... ... 2015 , ... With the goal of furthering music education programs in schools, ... Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by ... in the underfunded school districts of Mendon and its neighboring town of Quincy, IL. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The ... the renowned Brain Aneurysm Foundation has added yet another accolade to its cadre of ... Emanuel. , “With the help of the medical community and the University ...
(Date:8/28/2015)... , ... August 28, 2015 , ... “ Frequentz ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers how this software allows businesses to track product movement from beginning ...
(Date:8/28/2015)... ... 2015 , ... The Nashville Business Journal recently announced its ... Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one of ... Awards will recognize Nashville military veterans who, through their professional and personal efforts, ...
Breaking Medicine News(10 mins):Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2
... the safety of a potential vaccine against mesothelioma, a ... which infuses uses a patient,s own dendritic cells (DC) ... induce a T-cell response against mesothelioma tumors. "[This] ... patients with mesothelioma," wrote Joachim G Aerts M.D., Ph.D., ...
... A new iPhone app designed ... gone on sale on the App Store , ... (PRWeb UK) March 3, 2010 -- The Quickka Calories PRO iPhone app is aimed at ... items that they eat., , ,In what is being called a perfect union between technology and ...
... ... ... ... ...
... ... , ... , , , ... HOUSTON , March ...
... University of Texas M. D. Anderson Cancer Center, researchers found ... bladder cancer, is a cost-effective method of detecting tumors. ... well as the number of false positives that may result ... The study was presented today in advance of the American ...
... University of Washington,s Dr. H. Hunter Handsfield, a long-time ... the nation,s highest honor in the STD field during ... STD Prevention Conference in Atlanta, March 8-11. Handsfield ... named for Dr. Thomas Parran, Jr., U.S. Surgeon General ...
Cached Medicine News:Health News:Possible vaccine for mesothelioma proven safe 2Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 2Health News:Osteotech to Present at the Canaccord Adams Musculoskeletal Conference 3Health News:Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants 2Health News:Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 2Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 3Health News:Dr. Hunter Handsfield wins prestigious Thomas Parran Award 4
(Date:8/28/2015)... 28, 2015 According to a ... (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling ... Prognostic) & Geography - Global Forecast to 2020", published ... reach around 17,689.0 Million USD by 2020 at a ... to 2020. Browse 191 Tables and ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... subset analyses of progression-free survival in,the SPARC ... in,relative risk of disease progression for patients ... as well as presence or absence of ... Pharmion,Corporation and GPC Biotech AG today announced ...
... Results in Improved Long-term [Five-years],Overall Survival for ... 2007 /PRNewswire-FirstCall/ -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, ... survival (OS) and,time to disease progression (TTP) ... in patients with metastatic (advanced) colorectal cancer.,Importantly, ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4
... For use as a quality assurance ... human immunodeficiency virus type 1 (anti-HIV-1), ... I (anti-HTLV-I), antibody to hepatitis C ... core antigen (anti-HBc), antibody to cytomegalovirus ...
... the first,diagnostic hepatitis assay approved by the,U.S. ... in a random access format on,the VITROS ... run a hepatitis test at any time, ... for,the qualitative in vitro determination of total,antibody ...
... This SIGNET anti-PSA antibody gives ... all cases of benign hyperplasia. In ... intense staining and 34% give definite ... only a minority of cells; this ...
... kit is based on sequential binding of ... one (specific for the *-chain of HCG) ... (specific for the *-chain of HCG) conjugated ... washing step, chromogenic substrate is added and ...
Medicine Products: